|
GOLD guideline group
|
Phase 1 (n = 2358)
|
Phase 2 (n = 2177)
|
P value
|
|---|
|
Group A
|
1820 (77.2%)
|
1663 (76.4%)
|
0.31
|
|
Group B
|
399 (16.9%)
|
359 (16.5%)
|
|
Group C
|
78 (3.3%)
|
79 (3.6%)
|
|
Group D
|
61 (2.6%)
|
76 (3.5%)
|
- Group A: 0 or 1 moderate exacerbations (not leading to hospital admissions) AND mMRC 0–1 or CAT< 10.
- Group B: 0 or 1 moderate exacerbations (not leading to hospital admissions) AND mMRC ≥2 or CAT ≥10.
- Group C: ≥2 moderate exacerbations or ≥ 1 leading to hospitalization AND mMRC 0–1 or CAT< 10.
- Group D: ≥2 moderate exacerbations or ≥ 1 leading to hospitalization AND mMRC ≥2 or CAT ≥10.
- CAT = COPD assessment test; mMRC = modified Medical Research Council dyspnoea questionnaire.
